BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Daperno M, Castiglione F, de Ridder L, Dotan I, Färkkilä M, Florholmen J, Fraser G, Fries W, Hebuterne X, Lakatos PL. Results of the 2nd part Scientific Workshop of the ECCO. II: Measures and markers of prediction to achieve, detect, and monitor intestinal healing in inflammatory bowel disease. J Crohns Colitis. 2011;5:484-498. [PMID: 21939926 DOI: 10.1016/j.crohns.2011.07.003] [Cited by in Crossref: 72] [Cited by in F6Publishing: 67] [Article Influence: 6.5] [Reference Citation Analysis]
Number Citing Articles
1 Annese V, Daperno M, Rutter MD, Amiot A, Bossuyt P, East J, Ferrante M, Götz M, Katsanos KH, Kießlich R, Ordás I, Repici A, Rosa B, Sebastian S, Kucharzik T, Eliakim R. European evidence based consensus for endoscopy in inflammatory bowel disease. Journal of Crohn's and Colitis 2013;7:982-1018. [DOI: 10.1016/j.crohns.2013.09.016] [Cited by in Crossref: 486] [Cited by in F6Publishing: 410] [Article Influence: 54.0] [Reference Citation Analysis]
2 Rismo R, Olsen T, Ciu G, Paulssen EJ, Christiansen I, Florholmen J, Goll R. The effect of adalimumab for induction of endoscopic healing and normalization of mucosal cytokine gene expression in Crohn's disease. Scandinavian Journal of Gastroenterology 2012;47:1200-10. [DOI: 10.3109/00365521.2012.711853] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
3 Samant H, Desai D, Abraham P, Joshi A, Gupta T, Dherai A, Ashavaid T. Fecal calprotectin and its correlation with inflammatory markers and endoscopy in patients from India with inflammatory bowel disease. Indian J Gastroenterol 2015;34:431-5. [DOI: 10.1007/s12664-015-0608-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
4 Neumann H, Neurath MF. UCCIS—a reproducible tool to assess mucosal healing. Nat Rev Gastroenterol Hepatol 2012;9:692-4. [DOI: 10.1038/nrgastro.2012.198] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
5 Skamnelos A, Lazaridis N, Vlachou E, Koukias N, Apostolopoulos P, Murino A, Christodoulou D, Despott EJ. The role of small-bowel endoscopy in inflammatory bowel disease: an updated review on the state-of-the-art in 2021. Ann Gastroenterol 2021;34:599-611. [PMID: 34475730 DOI: 10.20524/aog.2021.0652] [Reference Citation Analysis]
6 Castiglione F, Mainenti P, Testa A, Imperatore N, De Palma GD, Maurea S, Rea M, Nardone OM, Sanges M, Caporaso N, Rispo A. Cross-sectional evaluation of transmural healing in patients with Crohn's disease on maintenance treatment with anti-TNF alpha agents. Dig Liver Dis 2017;49:484-9. [PMID: 28292640 DOI: 10.1016/j.dld.2017.02.014] [Cited by in Crossref: 51] [Cited by in F6Publishing: 44] [Article Influence: 10.2] [Reference Citation Analysis]
7 Papi C, Aratari A. Mucosal healing as a treatment for IBD? Expert Review of Gastroenterology & Hepatology 2014;8:457-9. [DOI: 10.1586/17474124.2014.902302] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
8 Yoon H, Jangi S, Dulai PS, Boland BS, Jairath V, Feagan BG, Sandborn WJ, Singh S. Histologic Remission Is Associated With Lower Risk of Treatment Failure in Patients With Crohn Disease in Endoscopic Remission. Inflamm Bowel Dis 2021;27:1277-84. [PMID: 33236763 DOI: 10.1093/ibd/izaa301] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Guardiola J, Lobatón T, Rodríguez-Alonso L, Ruiz-Cerulla A, Arajol C, Loayza C, Sanjuan X, Sánchez E, Rodríguez-Moranta F. Fecal level of calprotectin identifies histologic inflammation in patients with ulcerative colitis in clinical and endoscopic remission. Clin Gastroenterol Hepatol. 2014;12:1865-1870. [PMID: 24993368 DOI: 10.1016/j.cgh.2014.06.020] [Cited by in Crossref: 91] [Cited by in F6Publishing: 83] [Article Influence: 11.4] [Reference Citation Analysis]
10 Al-Hawary MM, Zimmermann EM, Hussain HK. MR imaging of the small bowel in Crohn disease. Magn Reson Imaging Clin N Am. 2014;22:13-22. [PMID: 24238129 DOI: 10.1016/j.mric.2013.09.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
11 Scaioli E, Sartini A, Bellanova M, Campieri M, Festi D, Bazzoli F, Belluzzi A. Eicosapentaenoic Acid Reduces Fecal Levels of Calprotectin and Prevents Relapse in Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol 2018;16:1268-1275.e2. [PMID: 29391271 DOI: 10.1016/j.cgh.2018.01.036] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 6.3] [Reference Citation Analysis]
12 Peyrin-Biroulet L, Sandborn WJ, Panaccione R, Domènech E, Pouillon L, Siegmund B, Danese S, Ghosh S. Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues. Therap Adv Gastroenterol 2021;14:17562848211059954. [PMID: 34917173 DOI: 10.1177/17562848211059954] [Reference Citation Analysis]
13 Jiao C, Zhang Q, Yang M, Ma J, Zhao X, Tang N, Dai M, Li Q, Jiang Z, Huang X, Zhang H, Sun L. Shenling Baizhu San ameliorates ulcerative colitis by regulating the gut microbiota and its tryptophan metabolites: A complementary medicine to mesalamine. J Ethnopharmacol 2022;:115145. [PMID: 35219821 DOI: 10.1016/j.jep.2022.115145] [Reference Citation Analysis]
14 Magro F, Lopes SI, Lopes J, Portela F, Cotter J, Lopes S, Moreira MJ, Lago P, Peixe P, Albuquerque A, Rodrigues S, Silva MR, Monteiro P, Lopes C, Monteiro L, Macedo G, Veloso L, Camila C, Afonso J, Geboes K, Carneiro F; Portuguese IBD group [GEDII]. Histological Outcomes and Predictive Value of Faecal Markers in Moderately to Severely Active Ulcerative Colitis Patients Receiving Infliximab. J Crohns Colitis 2016;10:1407-16. [PMID: 27226417 DOI: 10.1093/ecco-jcc/jjw112] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 5.0] [Reference Citation Analysis]
15 Giugliano FP, Strisciuglio C, Martinelli M, Andreozzi M, Cenni S, Campione S, D’armiento M, Staiano A, Miele E. Does Azathioprine induce endoscopic and histologic healing in pediatric inflammatory bowel disease? A prospective, observational study. Digestive and Liver Disease 2018;50:240-6. [DOI: 10.1016/j.dld.2017.10.017] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
16 Miheller P, Mandel MD, Mullner K, Lakatos PL. Clinical aspects of mucosal healing in inflammatory bowel diseases: what is it and what is the real value for the everyday practice? Expert Rev Clin Immunol 2013;9:871-82. [PMID: 24070050 DOI: 10.1586/1744666X.2013.824675] [Reference Citation Analysis]
17 Turvill J. Mapping of Crohn's disease outcomes to faecal calprotectin levels in patients maintained on biologic therapy. Frontline Gastroenterol 2014;5:167-75. [PMID: 28839766 DOI: 10.1136/flgastro-2014-100441] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
18 Saigusa K, Matsuoka K, Sugimoto S, Arai M, Kiyohara H, Takeshita K, Mizuno S, Mori K, Nanki K, Takeshita T, Nakazato Y, Yajima T, Naganuma M, Hisamatsu T, Ogata H, Iwao Y, Kanai T. Ulcerative colitis endoscopic index of severity is associated with long‐term prognosis in ulcerative colitis patients treated with infliximab. Digestive Endoscopy 2016;28:665-70. [DOI: 10.1111/den.12655] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
19 Kawashima K, Ishihara S, Yuki T, Fukuba N, Oshima N, Kazumori H, Sonoyama H, Yamashita N, Tada Y, Kusunoki R, Oka A, Mishima Y, Moriyama I, Kinoshita Y. Fecal calprotectin level correlated with both endoscopic severity and disease extent in ulcerative colitis. BMC Gastroenterol 2016;16:47. [PMID: 27071448 DOI: 10.1186/s12876-016-0462-z] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.7] [Reference Citation Analysis]
20 Zhou FS, Gao N, Sun X, Jiang XY, Chen JJ, Mao QQ, Zhong L. C-reactive protein/abumin ratio is a useful biomarker for predicting the mucosal healing in the Crohn disease: A retrospective study. Medicine (Baltimore) 2021;100:e24925. [PMID: 33725853 DOI: 10.1097/MD.0000000000024925] [Reference Citation Analysis]
21 Lobatón T, Rodríguez-moranta F, Lopez A, Sánchez E, Rodríguez-alonso L, Guardiola J. A New Rapid Quantitative Test for Fecal Calprotectin Predicts Endoscopic Activity in Ulcerative Colitis: . Inflammatory Bowel Diseases 2013;19:1034-42. [DOI: 10.1097/mib.0b013e3182802b6e] [Cited by in Crossref: 81] [Cited by in F6Publishing: 29] [Article Influence: 9.0] [Reference Citation Analysis]
22 Zallot C, Peyrin-Biroulet L. Deep remission in inflammatory bowel disease: looking beyond symptoms. Curr Gastroenterol Rep. 2013;15:315. [PMID: 23354742 DOI: 10.1007/s11894-013-0315-7] [Cited by in Crossref: 78] [Cited by in F6Publishing: 77] [Article Influence: 8.7] [Reference Citation Analysis]
23 Castiglione F, Testa A, Rea M, De Palma GD, Diaferia M, Musto D, Sasso F, Caporaso N, Rispo A. Transmural healing evaluated by bowel sonography in patients with Crohn’s disease on maintenance treatment with biologics. Inflamm Bowel Dis. 2013;19:1928-1934. [PMID: 23835441 DOI: 10.1097/mib.0b013e31829053ce] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
24 Magro F, Gionchetti P, Eliakim R, Ardizzone S, Armuzzi A, Barreiro-de Acosta M, Burisch J, Gecse KB, Hart AL, Hindryckx P. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. J Crohns Colitis. 2017;11:649-670. [PMID: 28158501 DOI: 10.1093/ecco-jcc/jjx008] [Cited by in Crossref: 682] [Cited by in F6Publishing: 563] [Article Influence: 170.5] [Reference Citation Analysis]
25 Magro F, Lopes S, Silva M, Coelho R, Portela F, Branquinho D, Correia L, Fernandes S, Cravo M, Caldeira P, Tavares de Sousa H, Patita M, Lago P, Ramos J, Afonso J, Redondo I, Machado P, Philip G, Lopes J, Carneiro F. Soluble human Suppression of Tumorigenicity 2 is associated with endoscopic activity in patients with moderate-to-severe ulcerative colitis treated with golimumab. Therap Adv Gastroenterol 2019;12:1756284819869141. [PMID: 31516554 DOI: 10.1177/1756284819869141] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
26 Hindryckx P, Novak G. Can we move directly from 5-ASA to a biologic agent in ulcerative colitis? Best Pract Res Clin Gastroenterol 2018;32-33:9-15. [PMID: 30060944 DOI: 10.1016/j.bpg.2018.05.004] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
27 Sachar DB; Biomarkers Task Force of the IOIBD. Role of biomarkers in the study and management of inflammatory bowel disease: a "nonsystematic" review. Inflamm Bowel Dis 2014;20:2511-8. [PMID: 25222663 DOI: 10.1097/MIB.0000000000000135] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
28 Kawashima K, Ishihara S, Yuki T, Fukuba N, Sonoyama H, Kazumori H, Yamashita N, Tada Y, Kusunoki R, Oka A, Oshima N, Mishima Y, Moriyama I, Kinoshita Y. Fecal Calprotectin More Accurately Predicts Endoscopic Remission of Crohn's Disease than Serological Biomarkers Evaluated Using Balloon-assisted Enteroscopy. Inflamm Bowel Dis 2017;23:2027-34. [PMID: 28817462 DOI: 10.1097/MIB.0000000000001202] [Cited by in Crossref: 23] [Cited by in F6Publishing: 9] [Article Influence: 5.8] [Reference Citation Analysis]
29 Bouguen G, Levesque BG, Pola S, Evans E, Sandborn WJ. Endoscopic assessment and treating to target increase the likelihood of mucosal healing in patients with Crohn's disease. Clin Gastroenterol Hepatol. 2014;12:978-985. [PMID: 24246770 DOI: 10.1016/j.cgh.2013.11.005] [Cited by in Crossref: 84] [Cited by in F6Publishing: 69] [Article Influence: 9.3] [Reference Citation Analysis]
30 Onal IK, Beyazit Y, Altinbas A, Kurt M, Arhan M. Maintenance therapy for Crohn's disease: should it be indefinite? Eur J Gastroenterol Hepatol. 2015; Jul 15. [Epub ahead of print]. [PMID: 26181109 DOI: 10.1097/MEG.0000000000000433] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
31 Oliva S, Thomson M, de Ridder L, Martín-de-Carpi J, Van Biervliet S, Braegger C, Dias JA, Kolacek S, Miele E, Buderus S, Bronsky J, Winter H, Navas-López VM, Assa A, Chong SKF, Afzal NA, Smets F, Shaoul R, Hussey S, Turner D, Cucchiara S. Endoscopy in Pediatric Inflammatory Bowel Disease: A Position Paper on Behalf of the Porto IBD Group of the European Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2018;67:414-30. [PMID: 30130311 DOI: 10.1097/MPG.0000000000002092] [Cited by in Crossref: 31] [Cited by in F6Publishing: 11] [Article Influence: 10.3] [Reference Citation Analysis]
32 Niv Y, Gal E, Gabovitz V, Hershkovitz M, Lichtenstein L, Avni I. Capsule Endoscopy Crohn's Disease Activity Index (CECDAIic or Niv Score) for the Small Bowel and Colon. J Clin Gastroenterol. 2018;52:45-49. [PMID: 27753700 DOI: 10.1097/mcg.0000000000000720] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
33 Bryant RV, Burger DC, Delo J, Walsh AJ, Thomas S, von Herbay A, Buchel OC, White L, Brain O, Keshav S, Warren BF, Travis SP. Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-up. Gut. 2016;65:408-414. [PMID: 25986946 DOI: 10.1136/gutjnl-2015-309598] [Cited by in Crossref: 190] [Cited by in F6Publishing: 173] [Article Influence: 27.1] [Reference Citation Analysis]
34 Miranda García P, Chaparro M, Gisbert JP. [Evaluation of the concordance between biological markers and clinical activity in inflammatory bowel disease]. Med Clin (Barc) 2015;144:9-13. [PMID: 24530050 DOI: 10.1016/j.medcli.2013.09.047] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
35 Sajjadi M, Gholamrezaei A, Daryani NE. No association between serum adenosine deaminase activity and disease activity in Crohn's disease. Dig Dis Sci. 2015;60:1755-1760. [PMID: 25652144 DOI: 10.1007/s10620-014-3510-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
36 Rismo R, Olsen T, Cui G, Paulssen EJ, Christiansen I, Johnsen K, Florholmen J, Goll R. Normalization of mucosal cytokine gene expression levels predicts long-term remission after discontinuation of anti-TNF therapy in Crohn’s disease. Scand J Gastroenterol. 2013;48:311-319. [PMID: 23302000 DOI: 10.3109/00365521.2012.758773] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 3.9] [Reference Citation Analysis]
37 Villanacci V, Antonelli E, Geboes K, Casella G, Bassotti G. Histological healing in inflammatory bowel disease: A still unfulfilled promise. World J Gastroenterol 2013; 19(7): 968-978 [PMID: 23467585 DOI: 10.3748/wjg.v19.i7.968] [Cited by in CrossRef: 57] [Cited by in F6Publishing: 55] [Article Influence: 6.3] [Reference Citation Analysis]
38 Tontini GE, Bisschops R, Neumann H. Endoscopic scoring systems for inflammatory bowel disease: pros and cons. Expert Rev Gastroenterol Hepatol. 2014;8:543-554. [PMID: 24650249 DOI: 10.1586/17474124.2014.899899] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
39 Cintolo M, Costantino G, Pallio S, Fries W. Mucosal healing in inflammatory bowel disease: Maintain or de-escalate therapy. World J Gastrointest Pathophysiol 2016; 7(1): 1-16 [PMID: 26909224 DOI: 10.4291/wjgp.v7.i1.1] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
40 Vega P, Valentín F, Cubiella J. Colorectal cancer diagnosis: Pitfalls and opportunities. World J Gastrointest Oncol 2015; 7(12): 422-433 [PMID: 26690833 DOI: 10.4251/wjgo.v7.i12.422] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 39] [Article Influence: 5.9] [Reference Citation Analysis]
41 Mosli MH, Sandborn WJ, Kim RB, Khanna R, Al-Judaibi B, Feagan BG. Toward a personalized medicine approach to the management of inflammatory bowel disease. Am J Gastroenterol 2014;109:994-1004. [PMID: 24842338 DOI: 10.1038/ajg.2014.110] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 5.0] [Reference Citation Analysis]
42 Scaioli E, Scagliarini M, Cardamone C, Liverani E, Ugolini G, Festi D, Bazzoli F, Belluzzi A. Clinical application of faecal calprotectin in ulcerative colitis patients. Eur J Gastroenterol Hepatol. 2015;27:1418-1424. [PMID: 26308711 DOI: 10.1097/meg.0000000000000461] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
43 Olsen T, Rismo R, Gundersen MD, Paulssen EJ, Johnsen K, Kvamme JM, Goll R, Florholmen J. Normalization of mucosal tumor necrosis factor-α: A new criterion for discontinuing infliximab therapy in ulcerative colitis. Cytokine 2016;79:90-5. [PMID: 26775117 DOI: 10.1016/j.cyto.2015.12.021] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
44 Iacucci M, Daperno M, Lazarev M, Arsenascu R, Tontini GE, Akinola O, Gui XS, Villanacci V, Goetz M, Lowerison M, Lethebe BC, Vecchi M, Neumann H, Ghosh S, Bisschops R, Kiesslich R. Development and reliability of the new endoscopic virtual chromoendoscopy score: the PICaSSO (Paddington International Virtual ChromoendoScopy ScOre) in ulcerative colitis. Gastrointestinal Endoscopy 2017;86:1118-1127.e5. [DOI: 10.1016/j.gie.2017.03.012] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 6.0] [Reference Citation Analysis]
45 Neubauer K, Kempinski R, Matusiewicz M, Bednarz-Misa I, Krzystek-Korpacka M. Nonenzymatic Serum Antioxidant Capacity in IBD and Its Association with the Severity of Bowel Inflammation and Corticosteroids Treatment. Medicina (Kaunas) 2019;55:E88. [PMID: 30986917 DOI: 10.3390/medicina55040088] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
46 Serban ED. Treat-to-target in Crohn’s disease: Will transmural healing become a therapeutic endpoint? World J Clin Cases 2018; 6(12): 501-513 [PMID: 30397606 DOI: 10.12998/wjcc.v6.i12.501] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
47 Neubauer K, Bednarz-Misa I, Walecka-Zacharska E, Wierzbicki J, Agrawal A, Gamian A, Krzystek-Korpacka M. Oversecretion and Overexpression of Nicotinamide Phosphoribosyltransferase/Pre-B Colony-Enhancing Factor/Visfatin in Inflammatory Bowel Disease Reflects the Disease Activity, Severity of Inflammatory Response and Hypoxia. Int J Mol Sci. 2019;20. [PMID: 30621173 DOI: 10.3390/ijms20010166] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
48 Castiglione F, Imperatore N, Testa A, De Palma GD, Nardone OM, Pellegrini L, Caporaso N, Rispo A. One-year clinical outcomes with biologics in Crohn's disease: transmural healing compared with mucosal or no healing. Aliment Pharmacol Ther 2019;49:1026-39. [DOI: 10.1111/apt.15190] [Cited by in Crossref: 42] [Cited by in F6Publishing: 30] [Article Influence: 14.0] [Reference Citation Analysis]
49 Magro F, Sousa P, Ministro P. C-reactive protein in Crohn's disease: how informative is it? Expert Rev Gastroenterol Hepatol. 2014;8:393-408. [PMID: 24635486 DOI: 10.1586/17474124.2014.893821] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
50 Bouguen G, Levesque BG, Feagan BG, Kavanaugh A, Peyrin–biroulet L, Colombel J, Hanauer SB, Sandborn WJ. Treat to Target: A Proposed New Paradigm for the Management of Crohn's Disease. Clinical Gastroenterology and Hepatology 2015;13:1042-1050.e2. [DOI: 10.1016/j.cgh.2013.09.006] [Cited by in Crossref: 163] [Cited by in F6Publishing: 143] [Article Influence: 23.3] [Reference Citation Analysis]
51 Puylaert CAJ, Nolthenius CJT, Tielbeek JAW, Makanyanga JC, Rodriguez-justo M, Brosens LAA, Nio CY, Pendsé DA, Ponsioen CY, Vos FM, Taylor SA, Stoker J. Comparison of MRI Activity Scoring Systems and Features for the Terminal Ileum in Patients With Crohn Disease. American Journal of Roentgenology 2019;212:W25-31. [DOI: 10.2214/ajr.18.19876] [Cited by in Crossref: 14] [Cited by in F6Publishing: 1] [Article Influence: 4.7] [Reference Citation Analysis]
52 Miheller P, Kiss LS, Juhasz M, Mandel M, Lakatos PL. Recommendations for identifying Crohn’s disease patients with poor prognosis. Expert Rev Clin Immunol. 2013;9:65-75; quiz 76. [PMID: 23256765 DOI: 10.1586/eci.12.86] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
53 Christensen B, Rubin DT. Understanding Endoscopic Disease Activity in IBD: How to Incorporate It into Practice. Curr Gastroenterol Rep 2016;18. [DOI: 10.1007/s11894-015-0477-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
54 Yuksel I, Kilincalp S, Coskun Y, Akinci H, Hamamci M, Alkan A. Diagnostic accuracy of intestinal ultrasound and magnetic resonance enterography for the detection of endoscopy-based disease activity in ileocolonic Crohn’s disease. European Journal of Gastroenterology & Hepatology 2019;31:809-16. [DOI: 10.1097/meg.0000000000001438] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
55 Boal Carvalho P, Cotter J. Mucosal Healing in Ulcerative Colitis: A Comprehensive Review. Drugs. 2017;77:159-173. [PMID: 28078646 DOI: 10.1007/s40265-016-0676-y] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 7.8] [Reference Citation Analysis]
56 Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG Clinical Guideline: Management of Crohn's Disease in Adults. Am J Gastroenterol. 2018;113:481-517. [PMID: 29610508 DOI: 10.1038/ajg.2018.27] [Cited by in Crossref: 390] [Cited by in F6Publishing: 311] [Article Influence: 97.5] [Reference Citation Analysis]
57 Chen H, Wu L, Wang M, Shao B, Ye L, Zhang Y, Cao Q. Use of the ulcerative colitis endoscopic index of severity and Mayo endoscopic score for predicting the therapeutic effect of mesalazine in patients with ulcerative colitis. Laparoscopic, Endoscopic and Robotic Surgery 2021;4:33-9. [DOI: 10.1016/j.lers.2021.04.003] [Reference Citation Analysis]
58 Onişor D, Boeriu A, Pascarenco O, Brusnic O, Dobru D. Role of fecal calprotectin as a biomarker of intestinal inflammation in ulcerative colitis: a prospective study. Revista Romana de Medicina de Laborator 2018;26:335-43. [DOI: 10.2478/rrlm-2018-0006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
59 De Greef E, Mahachie John JM, Hoffman I, Smets F, Van Biervliet S, Scaillon M, Hauser B, Paquot I, Alliet P, Arts W, Dewit O, Peeters H, Baert F, D'Haens G, Rahier JF, Etienne I, Bauraind O, Van Gossum A, Vermeire S, Fontaine F, Muls V, Louis E, Van de Mierop F, Coche JC, Van Steen K, Veereman G; IBD working group of the Belgian Society of Pediatric Gastroenterology, Hepatology and Nutrition (BeSPGHAN)., Belgian IBD Research and Development. Profile of pediatric Crohn's disease in Belgium. J Crohns Colitis 2013;7:e588-98. [PMID: 23664896 DOI: 10.1016/j.crohns.2013.04.016] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
60 Abitbol V, Borderie D, Polin V, Maksimovic F, Sarfati G, Esch A, Tabouret T, Dhooge M, Dreanic J, Perkins G. Diagnosis of Iron Deficiency in Inflammatory Bowel Disease by Transferrin Receptor-Ferritin Index. Medicine (Baltimore). 2015;94:e1011. [PMID: 26131803 DOI: 10.1097/md.0000000000001011] [Cited by in Crossref: 24] [Cited by in F6Publishing: 6] [Article Influence: 3.4] [Reference Citation Analysis]
61 Takashima S, Kato J, Hiraoka S, Nakarai A, Takei D, Inokuchi T, Sugihara Y, Takahara M, Harada K, Okada H, Tanaka T, Yamamoto K. Evaluation of Mucosal Healing in Ulcerative Colitis by Fecal Calprotectin Vs. Fecal Immunochemical Test. American Journal of Gastroenterology 2015;110:873-80. [DOI: 10.1038/ajg.2015.66] [Cited by in Crossref: 70] [Cited by in F6Publishing: 63] [Article Influence: 10.0] [Reference Citation Analysis]
62 Billiet T, Rutgeerts P, Ferrante M, Van Assche G, Vermeire S. Targeting TNF-α for the treatment of inflammatory bowel disease. Expert Opinion on Biological Therapy 2013;14:75-101. [DOI: 10.1517/14712598.2014.858695] [Cited by in Crossref: 85] [Cited by in F6Publishing: 88] [Article Influence: 9.4] [Reference Citation Analysis]
63 Puylaert CAJ, Tielbeek JAW, Schüffler PJ, Nio CY, Horsthuis K, Mearadji B, Ponsioen CY, Vos FM, Stoker J. Comparison of contrast-enhanced and diffusion-weighted MRI in assessment of the terminal ileum in Crohn’s disease patients. Abdom Radiol 2019;44:398-405. [DOI: 10.1007/s00261-018-1734-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
64 Castiglione F, Mainenti PP, De Palma GD, Testa A, Bucci L, Pesce G, Camera L, Diaferia M, Rea M, Caporaso N, Salvatore M, Rispo A. Noninvasive diagnosis of small bowel Crohn's disease: direct comparison of bowel sonography and magnetic resonance enterography. Inflamm Bowel Dis. 2013;19:991-998. [PMID: 23429465 DOI: 10.1097/mib.0b013e3182802b87] [Cited by in Crossref: 80] [Cited by in F6Publishing: 24] [Article Influence: 8.9] [Reference Citation Analysis]
65 Florholmen J. Mucosal healing in the era of biologic agents in treatment of inflammatory bowel disease. Scand J Gastroenterol. 2015;50:43-52. [PMID: 25523555 DOI: 10.3109/00365521.2014.977943] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
66 Laterza L, Piscaglia AC, Minordi LM, Scoleri I, Larosa L, Poscia A, Ingravalle F, Amato A, Alfieri S, Armuzzi A, Cammarota G, Gasbarrini A, Scaldaferri F. Multiparametric Evaluation Predicts Different Mid-Term Outcomes in Crohn's Disease. Dig Dis 2018;36:184-93. [PMID: 29514146 DOI: 10.1159/000487589] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
67 Helwig U, Fischer I, Hammer L, Kolterer S, Rath S, Maaser C, Kucharzik T. Transmural Response and Transmural Healing Defined by Intestinal Ultrasound - New Potential Therapeutic Targets? J Crohns Colitis 2021:jjab106. [PMID: 34185843 DOI: 10.1093/ecco-jcc/jjab106] [Reference Citation Analysis]
68 Lobatón T, Bessissow T, De Hertogh G, Lemmens B, Maedler C, Van Assche G, Vermeire S, Bisschops R, Rutgeerts P, Bitton A. The Modified Mayo Endoscopic Score (MMES): A New Index for the Assessment of Extension and Severity of Endoscopic Activity in Ulcerative Colitis Patients. J Crohns Colitis. 2015;9:846-852. [PMID: 26116558 DOI: 10.1093/ecco-jcc/jjv111] [Cited by in Crossref: 58] [Cited by in F6Publishing: 48] [Article Influence: 8.3] [Reference Citation Analysis]
69 Bryant RV, Winer S, Travis SP, Riddell RH. Systematic review: histological remission in inflammatory bowel disease. Is 'complete' remission the new treatment paradigm? J Crohns Colitis. 2014;8:1582-1597. [PMID: 25267173 DOI: 10.1016/j.crohns.2014.08.011] [Cited by in Crossref: 162] [Cited by in F6Publishing: 146] [Article Influence: 20.3] [Reference Citation Analysis]
70 Casciani E, Vincentiis CD, Gualdi G. Small bowel imaging of inflammatory bowel disease. World J Radiol 2015; 7(8): 198-201 [PMID: 26339463 DOI: 10.4329/wjr.v7.i8.198] [Cited by in CrossRef: 1] [Article Influence: 0.1] [Reference Citation Analysis]
71 Pagnini C, Menasci F, Desideri F, Corleto VD, Delle Fave G, Di Giulio E. Endoscopic scores for inflammatory bowel disease in the era of ‘mucosal healing’: Old problem, new perspectives. Digestive and Liver Disease 2016;48:703-8. [DOI: 10.1016/j.dld.2016.03.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
72 Tontini GE, Vecchi M, Pastorelli L, Neurath MF, Neumann H. Differential diagnosis in inflammatory bowel disease colitis: State of the art and future perspectives. World J Gastroenterol 2015; 21(1): 21-46 [PMID: 25574078 DOI: 10.3748/wjg.v21.i1.21] [Cited by in CrossRef: 91] [Cited by in F6Publishing: 76] [Article Influence: 13.0] [Reference Citation Analysis]